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Abstract
Background: Microarray studies in cancer compare expression levels between two or more
sample groups on thousands of genes. Data analysis follows a population-level approach (e.g.,
comparison of sample means) to identify differentially expressed genes. This leads to the discovery
of 'population-level' markers, i.e., genes with the expression patterns A > B and B > A. We
introduce the PPST test that identifies genes where a significantly large subset of cases exhibit
expression values beyond upper and lower thresholds observed in the control samples.
Results: Interestingly, the test identifies A > B and B < A pattern genes that are missed by
population-level approaches, such as the t-test, and many genes that exhibit both significant
overexpression and significant underexpression in statistically significantly large subsets of cancer
patients (ABA pattern genes). These patterns tend to show distributions that are unique to
individual genes, and are aptly visualized in a 'gene expression pattern grid'. The low degree of
among-gene correlations in these genes suggests unique underlying genomic pathologies and high
degree of unique tumor-specific differential expression. We compare the PPST and the ABA test
to the parametric and non-parametric t-test by analyzing two independently published data sets
from studies of progression in astrocytoma.
Conclusions: The PPST test resulted findings similar to the nonparametric t-test with higher self-
consistency. These tests and the gene expression pattern grid may be useful for the identification
of therapeutic targets and diagnostic or prognostic markers that are present only in subsets of
cancer patients, and provide a more complete portrait of differential expression in cancer.
Background
Studies of differential expression of individual genes often
find genes that are up-regulated in some tumors, and
down-regulated in others. Microarray studies typically
seek to identify differentially expressed genes using use
fold-change [1], t-tests [2], and models [3-6]. Studies of
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global gene expression patterns in cancer have focused
largely on the identification of novel cancer subtypes via
classification [7-13] or the identification of differentially
expressed genes [14-18]. Such studies typically use fold-
change [1], t-tests [2], and models [3-6]. The methods of
analysis for identifying differentially expressed genes in
data from microarray experiments vary widely [20-45],
but all are focused on the question of whether genes are
over-expressed or under-expressed in samples in group A
(e.g., tumor, or treatment, or metastastic, or responder)
compared to samples in group B (e.g., normal, or control,
or quiescient, or nonresponder). These patterns can effi-
ciently be referred to as AB (overexpressed in A) and BA
(underexpressed in A) patterns. Typically, researchers use
study designs that favor biological replication to maxi-
mize the ability to detect reproducibly genes that are dif-
ferentially expressed in a patient population, at a sacrifice
of the ability to detect individual-specific patterns of dif-
ferential expression with technical replication. Most can-
cers are diseases with heterogeneous etiologies; moreover,
the development of every primary tumor in different indi-
viduals is a unique biological event. Thus, the expression
levels of genes in the individual patient are also impor-
tant; some important gene dysregulation may be highly
specific to each individual. Statistical methods that aver-
age gene expression may hide important expressotypes
(expression phenotypes). Current tests that compare
mean group expression intensities are not likely to find
genes that are in fact significantly dysregulated in only a
proportion of the individuals in the case population,
unless the magnitude of differential expression is very
high in the subset of individuals. Unsupervised clustering
can be used to attempt to identify unknown partitions, or
subgroups within patients, but clustering is not a well-
defined method for finding differentially expressed genes,
and, upon discovery of novel groups, researchers are
restricted to comparing group means, and cannot identify
genes that may be dysregulated in subsets of patients
where the combined patterns of dysregulation patterns do
not suggest coherent subgroups.
Results
A remarkable pattern emerges when the PPST test is
applied to published cancer data sets, including breast
cancer [7], ovarian cancer [16], colon cancer (epithelial-
rich normals only [17,47]), lymphoma [18], and lung
cancer [19] at the 99th percentile. We find an abundance
of AB and BA pattern genes, with roughly the same
number of genes called significant under the parametric t-
test. We also find large numbers of genes with significant
ABA test scores, and some with 'BAB' pattern genes (Table
1). There is a marked tendency in most data sets for more
ABA (cancer-normal-cancer) type genes than BAB pattern
genes. These patterns are also reflected in 'expression pat-
tern grids' of gene with significant s3(ABA) statistics (Fig.
1). These patterns are reproducible at more stringent lev-
els of α (Table 1).
The capability of the PPST test to identify genes that are in
fact differentially expressed in only a subset of patients is
made evident by a comparison of genes that are found to
be significant under the PPST test, but missed by, for
example, the t-test (even without Bonferroni-type adjust-
ments). These are listed in Table 2, for the lymphoma
data18, and notably include B-cell growth factor 1 (IL4;
ABA pattern). Furthermore, 'classic' oncogenes such as
cyclin D1 are found by the PPST test in the lung cancer
data set [19] are not reported to be significant by the t-test.
Cyclin D1 ranks 1009th among significant genes in the
colon cancer data set under the t-test but ranks 90th under
the PPST test (AB/BA pattern results only).
Table 1: Number of Genes with Significant Differences between Tumor and Normal Class in Various Cancer Types under the PPST and 
ABA tests and the parametric t-test (for comparison)
α = 0.1 α = 0.05
Data Set PPST ABA test (ABA/BAB) PPST ABA test (ABA/BAB) parametric tα = 0.05 **
breast7 572 40/5 326 28/49 313
melanoma15 662 60/202 312 38/133 347
colon45 1788 55/153 1558 46/55 1378
ovarian16 3344 253/63 2060 189/22 1813
lymphoma18 2077 286/42 1114 194/30 1370
lung19 614 40/3 506 35/3 389
*A = tumor sample group, B = normal sample group **pooled variance tBMC Bioinformatics 2004, 5:110 http://www.biomedcentral.com/1471-2105/5/110
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Conceptual representation of AB, BA, and ABA patterns of differential expression Figure 1
Conceptual representation of AB, BA, and ABA patterns of differential expression. The colored tails represent the placement 
of expression values of a given gene in tumors when compared to the distribution of expression values in normal samples. 
Standard AB and BA patterns are represented by red and black, respectively. Cases in which a surprising number of samples 
are distributed in both tails for a given gene are represented here as green (BA) and red (AB), respectively, and are painted sim-
ilarly in Fig. 2 for specific samples.BMC Bioinformatics 2004, 5:110 http://www.biomedcentral.com/1471-2105/5/110
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Discussion
Our initial results are compelling in that they suggest that
we can expect biomarkers of high clinical significance for
subsets of patients to be important for distinct subsets of
patients. This also suggests that clinical validation of the
utility of biomarkers should examine panels of expression
biomarkers, not individual biomarkers. Disruption of
genomic function via these patterns cannot be studied in
the population level biomarker framework for the simple
reason that methods that compare, say, group means, will
find no difference between the sample groups if the
number of case samples found in the two tails are even
approximately equal. This is a sensible approach even
from within the framework of population-based hypoth-
esis testing, because the PPST test can be expected to be
more robust to one or two outliers that might mislead
simple parametric tests. Note that a number of genes are
'nearly significant' under the t-test but are strongly
significant under the PPST test for the AB/BA patterns
(e.g., Table 2).
Our re-analysis of two independently generated data sets
on astrocytoma progression demonstrates the utility of
extending analysis to include a search for genes that are
differentially expressed in a subset of patients. Of the tests
examined, the parametric t-test showed the least internal
consistency, while the PPST exhibited the highest internal
consistency in identifying progression markers. Compari-
son to the non-parametric t-tests demonstrates that PPST
is most similar to the nonparameteric t-test, but is more
self-consistent. While the ABA test showed the least inter-
nal consistency across populations, it also exhibited low
overlap with any other test, so the genes reported are
unique and tend not to be found by others tests, matching
expectations.
Our results are consistent with Knudsen's 'two-hit'
hypothesis on the genomic etiologies of cancer [49] with
some insight into the diversity of genomic pathologies
(functional 'hits') that may be relevant in patient popula-
tions. Studies of differential gene expression – and its role
in the etiology of cancer and its responses to treatment –
should seek these types of genes in addition to popula-
tion-wide biomarkers, because they represent a subset of
the genes that are expressed differentially in a significant
subset of cancer patients. We recommend a major shift in
perspective on the study on gene expression dysregulation
away from the study of 'tumor populations' – which do
not exist – toward the study of genomic pathologies in
individual patients. For example, tumor subtypes are
typically characterized by morphological characters, and
these classifications may conflict with important
expressotype subtypes that do not follow classical mor-
phological tumor classes. Imposition of these subtypes on
a study design may interfere with identifying expresso-
types that provide high diagnostic, prognostic and theran-
ostic value to the individual – and sets of individuals with
similar expressotypes. This view is also consistent with the
Hanahan-Weinberg model of oncogenesis [50], which
envisions multiple possible mechanistic strategies to the
acquisition of characteristics and capabilities of cancers
including self-sufficiency in growth signals, insensitivity
to anti-growth signals, tissue invasion & metastasis, limit-
less replicative potential, sustained angiogenesis and eva-
sion of apoptosis. We also expect that individual cancers
in different patients will be found to have evolved unique
sets of solutions to each of these problems. Current pre-
vailing methods for finding differentially expressed genes
such as fold-change and t-tests do not allow for such
complexities.
Our comparison of the methods (Table 3) highlights the
uniqueness of the ABA test. It is an extension of the PPST
test; it specifically focuses on genes that are differentially
expressed in subsets of patients. This ability is extremely
important in search of genes with expression patterns that
correlate with drug response. The ABA and the two-tailed
t-test are not comparable because the ABA test allows us to
Table 2: Exemplar Genes Found to the Significant (p < 0.05) under the PPST test in the lymphoma data set[18], but missed under the t-
test.
Gene PPST Score* Pattern p-value under t-test
B-cell growth factor (IL-4) 13 ABA 0.301
CCND1 Cyclin D1 (PRAD1; parathyroid 
adenomatosis 1)
13 AB 0.087
homeobox protein Cdx2 mRNA 12 AB 0.232
LIF Leukemia inhibitory factor (cholinergic 
differentiation factor)
10 AB 0.181
tumor susceptiblity protein (TSG101) mRNA -16 BA 0.526
carcinoembryonic antigen -18 BA 0.328
CCND2 Cyclin D2 -18 BA 0.076
VIM Vimentin -18 BA 0.976
*PPST Score = s1 or -s2 (for AB or BA pattern) and s3 (for ABA pattern)BMC Bioinformatics 2004, 5:110 http://www.biomedcentral.com/1471-2105/5/110
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find genes that the t-test specifically cannot (genes that are
simultaneously overexpressed in some patients while
underexpressed in others). Such test will have high vari-
ance (leading to a low t-test score) and low mean differ-
ence, and will thus not be significant. The PPST and the
ABA tests extend our abilities beyond the t-test. Other
improvements or even superior alternatives to these tests
may be possible. The performance of these tests and all
tests described to date for the AB type patterns and now
for ABA patterns should be compared using extensive
numerical simulations and cross-validation. Develop-
ments are needed to determine how best to select a thresh-
old to allow deliberate control of the false positive and
false negative error rates.
Conclusions
The two major conclusions these results suggest are (1)
that the most commonly applied tests for identifying dif-
ferentially expressed genes will miss important genes that
are dysregulated in only a fraction of patients, and (2) that
important aspects of differential expression may be, to a
degree, highly individualistic in most cancers. Some
potentially important genes with this form of unusual dif-
ferential expression (ABA; Table 2) would be missed by
methods that compare group means, because the means
of the two sample groups would be approximately identi-
cal, and the variance in tumors would be high, leading to
a large error term. The high internal consistency of PPST
compared to the non-parametric t-test and our observa-
tion that the PPST test exhibited high consistency with the
nonparametric t-test suggests that the PPST test may be of
interest to researchers interested in identifying both pop-
ulation-level biomarkers and biomarkers important to a
subset of patients.
An online implementation of this test, it source code
(Java), and that for many other methods of analysis, are
accessible online in the Cancer Gene Expression Data
Analysis tool http://bioinformatics.upmc.edu/. It is
hoped that the development and application of more
approaches like this will lead to a more complete repre-
sentation of differential expression, leading to more
meaningful and specific hypotheses of dysregulation, and
thus a better comprehension of how diverse genomic
pathologies contribute to the etiologies of cancers, and
Table 3: Summary of the overlap study of the two astrocytoma progression marker data sets. A. Internal consistency of the methods 
under comparison. k = Khatua et al. data set51; vdb = van den Boom et al. data set52 B. Number of significant genes that overlap between 
the two data sets in the significant gene list for each method. C. Comparison (% overlap) of methods in the k data set. D. Comparison 
(% overlap) of methods in the vdb data set
A % overlap k












k t-test (p) t-test (np) PPST ABA
Test 2 t-test (p) 1 78.527 74.394 2.579




D v t-test (p) t-test (np) PPST ABA
Test 2 t-test (p) 1 46.382 26.649 0
t-test (np) 1 56.975 5.656
PPST 1 7.268
ABA 1BMC Bioinformatics 2004, 5:110 http://www.biomedcentral.com/1471-2105/5/110
Page 6 of 9
(page number not for citation purposes)
thereby facilitate the identification of targets that may lead
to individual-specific therapies.
Methods
We have developed a test we call the Permutation Percen-
tile Separability Test (PPST), which attempts to refute a
null hypothesis that is slightly different from A = B, but
which is capable of detecting AB, BA, ABA and BAB pat-
terns. Under this test, we are interested in the question
"are there are statistically significant number of samples in
group A (e.g., tumor) that exhibit expression intensities
beyond a particular percentile of the observed expression
intensities in group B (e.g., normal)?" and vice versa. By
'statistically significant' we mean that the number of
samples that exhibit apparent overexpression (or underex-
pression) exceeds that expected under the null
distribution.
To test these hypotheses, we count the number of samples
in both groups that are found beyond the nth percentile of
the samples in the opposite group. This provides two
scores, s1, and s2, for each gene (PPST scores). s1 is the
number of samples in group A that are beyond the upper
percentile (say, 95th) of group B plus the number of sam-
ples in group B that are below the lower 95th percentile of
group A. This measure will tend to be large when all sam-
ples in both groups are significantly distinct from the
alternate group in the same way (comparisons consistent
with A > B). It can also be significant when a surprising
number of samples in only one group varies from the
expression levels in the alternate group. s2 is the number
of samples with correspondingly opposite pattern (com-
parisons consistent with B > A). Sample class label permu-
tations are used to generate an arbitrarily large number of
permuted data sets. These scores s1 and s2 are calculated in
each permuted data set to produce unique null distribu-
tions for each gene. For the sake of convenience of inter-
pretation, we use -s2  when reporting s2  to denote
underexpression. Genes with values of s1 beyond the spec-
ified acceptable Type 1 error risk (e.g., α = 5%) are deter-
mined to be significantly overexpressed in sample group
A relative to B. Individuals in sample group A with expres-
sion intensity values  over the 95th percentile of sample
group B for a given gene may be considered overex-
pressed. Similarly, genes with values of s2 beyond the spec-
ified Type 1 risk for s2 are deemed underexpressed in
sample group B relative to A. Varying the percentile
threshold allows direct control over the false discovery
rate.
Test for ABA patterns (ABA Test)
Genes that exhibit both significant s1 and s2 scores in this
comparison may be considered 'ABA pattern genes' (Fig.
1); however, for stronger inference, permutation tests are
also used to calculate s3, to determine, for a given gene, the
number of samples from one group (A) that can expected
to be distributed both in the upper and lower nth percen-
tile tails of the intensity distribution of that gene in the
other group (B); i.e., in the ABA (s3) or BAB (s4) pattern.
These scores are not redundant to but rather allow for
exploration of distribution-wise (upper and lower) false
discovery rates. The application of the PPST test to find
ABA patterns is called the 'ABA' test. Under the ABA test,
differential expression of a gene may be deemed to be sig-
nificant in both directions at once, i.e., simultaneously
significantly over-expressed and under-expressed in a sur-
prising number of patients in the case population. Both
the PPST test and the ABA test will perform optimally
when the variation in expression intensities in the normal
sample population is well characterized.
A collection of published microarray data sets we have
placed 'on-tap' in the caGEDA (Gene Expression Data
Analysis) web application http://bioinformat
ics.upmc.edu/GE2/GEDA.html[51] were subjected to the
PPST test and the ABA test. To avoid idiosyncracies that
can result from the study of extreme values, we ran the
tests at a fairly relaxed Type 1 error risk (α = 0.05 in both
tails, or α = 0.10 overall). To compare the self-consistency
of the parametric t-test, the nonparametric t-test, the PPST
test and the ABA test, we re-analyzed two published data
sets from independent astrocytoma progression studies
[52,53]. Details of these studies are available in the origi-
nal papers. In brief, Khatua et al. [52] studied global gene
expression profiles from 6 early stage and 7 late-stage
astrocytoma patients, while van den boom et al. [53]
studied global gene expression profiles from 8 early stage
and 8 late-stage astrocytoma patients. We calculated the
overlap in the gene lists using our online Overlap tool
http://bioinformatics.upmc.edu/GE2/Overlap.html.
Abbreviations
PPST: permutation percentile separability test.
ABA test: a test that can detect genes with both A > B (gene
is overexpressed in sample A compared to sample group
B) and B < A (gene is overexpressed in sample B compared
to sample group A) patterns.
s1, s2, s3, s4: measures of the number of samples that
exhibit expression intensities beyond a specified percen-
tile in an alternate group; used as scores in the determina-
tion of significance under the PPST and ABA tests.
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Gene Expression Pattern Grid of genes with significant ABA patterns from a comparison of epithelial-like normal colon tissue  (blue samples) to colon cancers (red samples; Alon et al, 1999) Figure 2
Gene Expression Pattern Grid of genes with significant ABA patterns from a comparison of epithelial-like normal colon tissue 
(blue samples) to colon cancers (red samples; Alon et al, 1999). We have previously determined that 5 samples in the Alon et 
al. data set were epithelial-like normal using unsupervised bootstrap cluster analysis and removed the remaining muscle-like 
normals from this analysis. These, and many other published cancer microarray data sets are 'on-tap' in our GEDA web appli-
cation. The Gene Expression Pattern Grid, which is generated for any set of differentially expressed genes with the GEDA web 
application, summarizes the types of differential expression in a way that is related to the PPST test. Color signifies that an indi-
vidual in one group exhibits an expression value that is significantly different from the expression pattern in the other group 
(red = overexpression; green = underexpression). Black signifies that an individual exhibits an expression value within the spec-
ified upper and lower percentiles in the other group. Tumor samples that fall within the upper and lower 95th %tiles of the dis-
tribution of expression values from the normal samples are labeled black, showing which genes for which a sample is are not 
different from normal. This representation includes information on both the population-level informativeness as well as which 
individuals appear to exhibit uniquely differentially expressed profiles. Samples within sample group are arranged according to 
their relative position in a hierarchical agglomerative clustering with pairwise distance = 1-Pearson's correlation coefficient. 
'Not expressed' is a hypothesis generated in these graphs when the expression intensity value of that gene for that individual 
falls in the lower 95th %tile of the entire data set. Expression pattern grids were produced online with the Gene Expression 
Data Analysis web application http://bioinformatics.upmc.edu/.BMC Bioinformatics 2004, 5:110 http://www.biomedcentral.com/1471-2105/5/110
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